Gilead Sciences Stock News

Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time Baird Global Healthcare Conference o...

The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth t...

Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.

Although the market may have hit a calm relative to the wild volatility witnessed earlier this month, we may not be out of the woods yet. Sure, the CBOE Volatility Index or the VIX has come down significantly from its earlier highs.

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.

AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.

Revenue of $7.0 billion, up 6% excluding Veklury. Non-GAAP diluted EPS of $2.01.